







Sector leading performance across various ESG ratings providers

Agency	Rating	Score		Industry perspective ⁹
		Current	Previous	
 ¹	Score	▲ 4.18	3.2	2 / 20
 ²	Climate score	▼ B	A-	Management band B/B- ¹⁰
	Water score	▼ A-	A	Leadership band A/A- ¹⁰
 ³	ESG score	▶ B	B	2 / 491
 ^{2,4}	ESG rating ⁵	▲ AA	A	Best rated peers: AAA (3 PharmaCos), AA (10 PharmaCos)
	MSCI Global Compact ⁶	▲ Pass	Watchlist	
	Controversy ^{6,7}	▲ 3	1	
 ^{2,4}	ESG score	▲ 84	73	5 / 91 in Pharmaceuticals (97 th percentile)
 ³	Risk score	▶ 16.9 ⁸	16.9	1 / 456 in Pharmaceutical subindustry group ¹¹

1. Published every 2nd year. Result shown shows 2020/2018 scores 2. 2021/2020 scores 3. 2022/2021. Updated October 2022 4. Updated March 2022. Novartis has been a DJSI World member since 2002 5. Updated June 2022 6. Updated December 2021 7. 0-10 scale, 0 being most severe controversy 8. Updated October 2022 9. Leadership as defined by rating agencies 10. Climate: Novartis received a B (Management band), same as the Biotech & pharma sector average, Water: Novartis received a A-(Leadership band), higher than the Biotech & pharma sector average 11. Pharmaceuticals subindustry group: traditional Pharma, excl. Biotech